ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1437

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study

William R Tillett1, Joseph Merola2, Yoshiya Tanaka3, Ennio G Favalli4, Dennis McGonagle5, Jessica A Walsh6, Diamant Thaçi7, Barbara Ink8, Rajan Bajracharya8, Vanessa Taieb9 and Christopher T Ritchlin10, 1Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Harvard Medical School, Brigham and Women's Hospital, Newton, MA, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, 5Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, 6Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 7Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 8UCB Pharma, Slough, United Kingdom, 9UCB Pharma, Colombes, France, 10University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY

Meeting: ACR Convergence 2023

Keywords: Disease Activity, Psoriatic arthritis, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Given the chronic nature of PsA, sustaining high levels of disease control with treatment is important. Assessing maintenance of response in patients (pts) that achieve treatment targets is of interest as pts can experience loss of response with long-term therapy.1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated rapid, clinically meaningful joint and skin efficacy responses at Week (Wk) 16 versus placebo (PBO) in pts with PsA.2,3 Responses were sustained to Wk 52.4 We report maintenance of response in joint and skin efficacy outcomes to Wk 52 in BKZ-treated pts with PsA who responded at Wk 16.

Methods: BE OPTIMAL (NCT03895203), which included a 16-wk double-blind, PBO-controlled period and a 36-wk active treatment-blind period, assessed BKZ in patients with active PsA who were biologic DMARD (bDMARD)-naïve. Pts were randomized 3:2:1 to subcutaneous BKZ 160 mg every 4 wks (Q4W), PBO, or reference (adalimumab 40 mg Q2W). At Wk 16, PBO pts switched to BKZ 160 mg Q4W. Maintenance of response is reported as the percentage of BKZ-treated pts who achieved response at Wk 16 and maintained response at Wk 52. Data are reported for pts randomized to BKZ 160 mg Q4W at baseline (BL). Endpoints include ACR20/50/70, Psoriasis Area and Severity Index (PASI)75/90/100, minimal and very low disease activity (MDA, VLDA), and Disease Activity Index for PsA (DAPSA) remission or low disease activity (REM+LDA; ≤14) and remission (REM; ≤4) responses. Wk 16 responders are reported using non-responder imputation (NRI); maintenance of response to Wk 52 is reported using NRI and observed case (OC). Treatment-emergent adverse events (TEAEs) to Wk 52 are reported for pts who received ≥1 dose of BKZ, including pts randomized to PBO at BL.

Results: At BL, 431 pts were randomized to BKZ 160 mg Q4W; 217/431 (50.3%) had psoriasis affecting ≥3% of body surface area (BSA). 414/431 (96.1%) completed Wk 16; 388 (90.0%) completed Wk 52. Most pts who achieved response at Wk 16 maintained response at Wk 52, across a range of outcomes (Figure). At Wk 16, ACR20/50/70 was achieved by 268 (62.2%)/189 (43.9%)/105 (24.4%) pts; responses were maintained at Wk 52 by 88.4%/86.8%/82.9% (NRI); 92.9%/91.1%/87.9% (OC). Of 217 pts with psoriasis affecting ≥3% of BSA at BL, 133 (61.3%)/103 (47.5%) achieved PASI90/100 at Wk 16. Most pts maintained response at Wk 52: 82.7%, 79.6% (NRI); 94.0%, 89.1% (OC). The same pattern was observed for the composite measures of efficacy. 194 (45.0%) pts achieved MDA at Wk 16; 85.6% (NRI) and 90.7% (OC) maintained response at Wk 52. A high proportion of Wk 16 responders maintained their response at Wk 52 for VLDA, DAPSA REM+LDA, and DAPSA REM (Figure). To Wk 52, 555/702 (79.1%) BKZ-treated pts reported ≥1 TEAE; 46 (6.6%) reported serious TEAEs.

Conclusion: With BKZ treatment, Wk 16 responders maintained robust efficacy responses to Wk 52 across joint, skin, and composite efficacy outcomes. The safety profile of BKZ was consistent with previous reports.2,3

References:1. Boehncke WH. Am J Clin Dermatol 2013;14:377–88; 2. McInnes IB. Lancet 2022; 401(10370):25-37; 3. Merola JF. Lancet 2022; 401(10370):38-48; 4. Ritchlin C. Arthritis Rheumatol 2022;74(suppl 9).

Supporting image 1

Figure. Maintenance efficacy responses to Week 52 in Week 16 responders (NRI)


Disclosures: W. Tillett: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 2, 5, 6, GSK, 2, 5, 6, Janssen, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Ovo Pharma, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma, 2, 5, 6; J. Merola: Abbvie, 2, 12, Investigator, Amgen, 2, 12, Investigator, Biogen, 2, 12, Investigator, Bristol-Myers Squibb, 2, 12, Investigator, Dermavant, 2, 12, Investigator, Eli Lilly, 2, 6, 12, Investigator, Janssen, 2, 12, Investigator, Leo Pharma, 2, 12, Investigator, Novartis, 2, 12, Investigator, Pfizer, 2, 12, Investigator, Regeneron, 2, 12, Investigator, Sanofi, 2, 12, Investigator, Sun Pharma, 2, 12, Investigator, UCB Pharma, 2, 12, Investigator; Y. Tanaka: AbbVie, 6, AstraZeneca, 6, BMS, 6, Boehringer-Ingelheim, 6, Chugai, 5, 6, Eisai, 5, 6, Eli Lilly, 6, Gilead, 6, GSK, 6, Mitsubishi-Tanabe, 5, Pfizer, 6, Taiho, 6, Taisho, 5, 6; E. Favalli: AbbVie, 2, 6, Bristol-Myers Squibb (BMS), 2, 6, Celltrion, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB Pharma, 2, 6; D. McGonagle: AbbVie, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 5, 6, 12, Paid Instructor, Janssen, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; J. Walsh: AbbVie, 5, Amgen, 2, Eli Lilly, 2, Janssen, 2, Merck, 5, Novartis, 2, Pfizer, 2, 5, UCB Pharma, 2; D. Thaçi: AbbVie, 1, 2, 5, 12, Investigator, Almirall, 1, 2, 12, Investigator, Amgen, 1, 2, 12, Investigator, Boehringer-Ingelheim, 1, 2, 12, Investigator, Bristol-Myers Squibb(BMS), 1, 2, 12, Investigator, Celltrion, 1, 2, 12, Investigator, Eli Lilly, 1, 2, 12, Investigator, Galapagos, 1, 2, 12, Investigator, Galderma, 1, 2, 5, 12, Investigator, Janssen-Cilag, 1, 2, 12, Investigator, LEO Pharma, 1, 2, 5, 12, Investigator, Novartis, 1, 2, 5, 12, Investigator, Pfizer, 1, 2, 12, Investigator, Regeneron, 1, 2, 12, Investigator, Samsung, 1, 2, 12, Investigator, Sandoz, 1, 2, 12, Investigator, Sanofi, 1, 2, 12, Investigator, Target-Solution, 1, 2, 12, Investigator, UCB, 1, 2, 12, Investigator; B. Ink: AbbVie, 11, GSK, 11, UCB Pharma, 3, 11; R. Bajracharya: UCB Pharma, 3, 11; V. Taieb: UCB Pharma, 3, 11; C. Ritchlin: AbbVie, 2, 5, 6, Amgen, 2, BMS, 2, Eli Lilly, 2, Gilead, 2, Janssen, 2, Novartis, 2, Pfizer, 2, 5, 6, UCB, 2, 6.

To cite this abstract in AMA style:

Tillett W, Merola J, Tanaka Y, Favalli E, McGonagle D, Walsh J, Thaçi D, Ink B, Bajracharya R, Taieb V, Ritchlin C. Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/bimekizumab-maintained-efficacy-responses-through-52-weeks-in-biologic-disease-modifying-antirheumatic-drug-naive-patients-with-psoriatic-arthritis-who-were-responders-at-week-16-results-from-a-phase/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bimekizumab-maintained-efficacy-responses-through-52-weeks-in-biologic-disease-modifying-antirheumatic-drug-naive-patients-with-psoriatic-arthritis-who-were-responders-at-week-16-results-from-a-phase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology